A post-hoc analysis from SHIFT assessed the impact of ivabradine on early readmissions in patients hospitalized for heart failure. Ivabradine significantly reduced the risk of early recurrent hospitalizations following a first heart failure hospitalization. This reduction of risk was significant from the first month onwards (30% relative risk reduction, P<0.05), ranging from 21% to 30% within the first 3 months following a heart failure hospitalization.
Komajda M, Tavazzi L, Swedberg K, et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. Eur J Heart Fail. 2016;18(9):1182-1189.
Published in May 2015
An analysis from the SHIFT trial assessed the impact of multiple comorbidities on outcomes and the potential impact on the benefits of ivabradine in heart failure patients. Multimorbidity was associated with a higher risk of outcomes but, whatever the number of comorbidities, did not interfere with the effects of ivabradine in reducing the primary end point of cardiovascular death or hospitalization for heart failure or in reducing other heart failure-related outcomes. Continue reading
Published in April 2015
The SHIFT Prognostic Model is based on simple clinical characteristics (increased resting HR, low ejection fraction, raised creatinine, New York Heart Association class III/IV, longer duration of HF, history of left bundle branch block, low systolic blood pressure, age…) to provide prognostic information in patients with chronic heart failure, systolic dysfunction, and elevated HR1. Continue reading